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Purpose: Temporal arteritis (TA) is frequently diagnosed with nonspecific clinical characteristics, followed by a temporal
artery biopsy to confirm the presence of vasculitis. Consequently, numerous screening surgical biopsies are performed
with a high negative-biopsy rate. A prospective study was performed evaluating color duplex ultrasound scan (CDU) as
the preferred method for the diagnosis of vasculitis in the evaluation of suspected TA.
Methods: Thirty-two patients with suspected TA on the basis of clinical criteria were evaluated with CDU before a
temporal artery biopsy. The presence of a hypoechoic “halo,” suggesting edema of the inflamed vessel, and inflammatory
stenoses were noted. Histologic examinations of standard temporal artery biopsies then were performed, and the results
were compared with the CDU findings. In addition, a metaanalysis was performed to identify articles related to the use
of ultrasound scan in the detection of TA.
Results: All patients completed a bilateral CDU examination of the temporal arteries, and in 75% of patients biopsied, no
evidence of vasculitis was found at histologic examination. When CDU examined for halo alone as the determinant for
disease, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), compared with
histologic confirmation of TA, were 85.7%, 92.0%, 75.0%, and 95.8%, respectively. With the criteria for a halo sign
present, an inflammatory stenosis present, or both present on CDU, the sensitivity, specificity, positive predictive value,
and NPV were 100%, 80.0%, 58.3%, and 100%, respectively.
Conclusion: CDU is a superior noninvasive method of determining the presence of vasculitis when compared with routine
surgical biopsy. Examination of the temporal artery with CDU can effectively predict which patient will need surgical
biopsy. The utility of CDU in the diagnosis of TA is maintained by a high sensitivity in detecting patients with the disease
and also by a high NPV that can eliminate patients who would not benefit from biopsy. (J Vasc Surg 2002;36:1154-60.)
The management of temporal arteritis (TA) can be a
clinical challenge secondary to the nonspecific clinical
symptoms associated with the diagnosis of this disorder.
Because TA is the second leading cause of acquired blind-
ness in this country, prompt recognition of this inflamma-
tory vasculitis is necessary to begin appropriate treatment
with systemic corticosteroid therapy. The common nature
of disease presentation, and the threat of early disease
progression, often lead physicians to temporal artery biopsy
as a method of screening for this disease.1 To further clarify
the diagnosis for TA, the American College of Rheumatol-
ogy has established diagnostic criteria, with temporal artery
biopsy remaining only one of five criteria2 (Table I). In
spite of this, temporal artery biopsy is still the hallmark of a
conclusive diagnosis, and many physicians are reluctant to
subject patients to the dangers of long-term high-dose
steroid therapy without some direct evidence of active
inflammatory vasculitis.3 Also, temporal artery biopsy re-
sults are frequently negative despite the presence of clini-
cally relevant features, with most research models unable to
identify any set of characteristics that would be highly
predictive of a positive biopsy result.1 Consequently, surgical
biopsy is sought in a population with a relatively low preva-
lence of disease, yielding a high rate of negative biopsy results.
Ultrasonography may be one additional method to help
physicians diagnose this challenging disease. This confusing
clinical picture allows noninvasive testing to help physicians
better predict TA before sending patients for a confirmatory
surgical biopsy. To eliminate a population that would not
benefit from biopsy, a screening test must have a high sensi-
tivity and negative predictive value (NPV) for the disease in
the population studied. Recent technologic advances with color
duplex ultrasound scan (CDU) to image superficial vascular
structures and determine patency and flow characteristics of
these vessels can allow detailed assessment of temporal arterial
segments. In patients with clinical findings, active symptoms,
and an inflammatory vasculitis with histology, a hypoechoic
“halo” has been previously shown with ultrasound scan in a
periarterial distribution, suggesting edema from an active in-
flammatory process4 (Figs 1 and 2). Surgical biopsy after the
demonstration of the ultrasound scan halo or temporal artery
stenoses has been found to be highly predictive of TA, with an
ability to eliminate patients who would not benefit from
biopsy
4-9
(Fig 3). This study was performed in concert with an
analysis of pertinent world literature to evaluate the potential
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of CDU as the initial screening test before surgical biopsy of
the temporal artery in the diagnosis of giant cell arteritis.
METHODS
Patients. A prospective study of all patients with sus-
pected TA referred to a university-affiliated vascular surgi-
cal group from November 1997 to April 2001 was under-
taken. All patients referred for surgical biopsy with clinical
symptoms suggestive of TA were evaluated with CDU
before scheduling of surgical biopsy. These patients were
free from a prior diagnosis of TA and had not undergone
temporal artery biopsy at any time in the past. The surgical
biopsy was performed bilaterally unless specifically directed
by the referring physician.
Technique. CDU was performed bilaterally on the
temporal arteries with a high-resolution linear transducer
(L 10-5 MHz or L 7-5 MHz) with ATL 5000, 3000, or
Ultramark 9 HDI (ATL Ultrasound, Inc, Bothell, Wash),
as described previously in the literature.9 This examination
can be tedious because of the small size of the vessels,
frequent tortuosity, and location of the arterial segments
below the scalp above the hairline. Despite the intricacies of
the study, technologists experienced in arterial duplex scan
can master the anatomy quickly and perform the test in
approximately 30 minutes. The common superficial tem-
poral arteries were established as landmarks medial to the
ear and then followed superiorly to the frontal and parietal
branches of the temporal artery. The vessels were followed
in longitudinal and transverse planes throughout the exam-
ination, with and without color flow, looking for the halo
effect or arterial stenoses. A halo was defined as a hypoechoic
or anechoic region surrounding the perfused lumen of the
temporal artery or branches for a discrete region. Peak systolic
velocities were obtained throughout the temporal arteries and
branches, and a stenosis was defined as at least a two-fold
increase of the peak systolic velocity accompanied by postste-
notic turbulence.10 Calcification and irregularities were noted
in arterial segments if hemodynamically significant stenoses
were present. All biopsies attempted to provide a specimen
length of 5 cm with a minimum specimen length of 2.5 cm.
Metaanalysis. A Medline search was done to identify
all published papers related to the use of ultrasonography in
the diagnosis of TA. Six papers were identified that met the
following criteria to be included in a statistical analysis of
CDU for the diagnosis of TA: 1, the study had to be
prospective; 2, duplex ultrasound scan technology was used
to evaluate for halo or stenosis; and 3, the results were to be
confirmed with temporal artery biopsy. The results of these
studies were examined, and the data were extracted and com-
bined with that from our study to formulate a more complete
set for statistical analysis. The sensitivity, specificity, positive
predictive value (PPV), NPV, accuracy of the diagnostic data,
and positive and negative likelihood ratios were calculated.
RESULTS
Thirty-two patients were referred for surgical biopsy of
the temporal arteries during this study period, and all were
preoperatively evaluated with a bilateral temporal artery
CDU examination. In this study, 75% of the patients had
bilateral biopsies performed and all CDU results were
compared with histologic findings. The average age of the
patients seen at our clinic was 73.1 years ( 9.2 years), with
21 women (65.6%) and 11 men (34.4%). The clinical
symptoms and physical findings of patients at presentation
were headache in 24 (75.0%), elevated erythrocyte sedi-
mentation rate in 17 (53.1%), visual changes in eight
(25.0%), temporal artery tenderness or pain in seven
(21.9%), and transient ischemic attack, polymyalgia rheu-
matica, and sudden monocular blindness in one patient
each. All nine patients who were shown to be histologically
positive for vasculitis or had an ultrasound scan halo present
had either a headache (n 7; 77.8%) or visual changes (n
3; 33.3%) as the most constant findings. All patients toler-
ated the CDU examination without difficulty, and no sur-
gical complications occurred.
In this cohort, eight patients showed a hypoechoic halo
around a patent temporal artery shown with CDU, and 24
patients showed no evidence of an inflammatory halo. Of
these eight patients with the halo sign present, five were
confined to the superficial temporal artery and three were
Fig 1. Halo sign is visualized as hypoechoic region around per-
fused lumen of temporal artery.
Table I. Diagnostic criteria for TA
The American College of Rheumatology
Age 50 years
Sudden onset of localized headache
Temporal tenderness or decreased pulse
ESR  50 mm/h
Histologic findings of inflammation
Three of five criteria must be present for diagnosis of TA.
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confined to additional temporal artery branches. In five
patients, bilateral halos were shown. Pathologic evaluation
of the biopsy specimens was positive in six of the eight
patients with a halo and showed evidence of giant cell
arteritis in three and arterial inflammatory changes without
definite cellular infiltrates in three. A halo was present in
two remaining patients, one with a hemodynamically sig-
nificant stenosis associated with bilateral halos and the
other with no stenosis. These patients had negative biopsy
results and for the purposes of this study were considered to
have a false-positive result for halo.
Inflammatory stenoses within the temporal artery are
also a predictor of this disease and are evaluated with noting
CDU flow hemodynamics. A hemodynamically significant
stenosis was found in seven of the 32 patients: three were
histologically confirmed for vasculitis, three were con-
firmed as atherosclerotic plaque with pathology, and one
had a negative biopsy result despite the presence of bilateral
Fig 2. Halo sign clearly shows periarterial edema seen in patient with vascular inflammation and biopsy-proven TA.
Fig 3. Inflammatory stenosis was visualized in patient with TA with increase of peak systolic velocity from 56 cm/s to
115 cm/s accompanied by poststenotic turbulence.
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halos. At surgical biopsy, seven of the 32 patients were
shown to have histologically confirmed inflammatory vas-
culitis. One of these patients had been on steroid therapy
for 10 days before the CDU examination, and no evidence
of halo was found although bilateral stenoses were present.
This result was considered a false-negative result for halo in
this study.
All patients with histologically confirmed vasculitis or
halo were treated with corticosteroid therapy with resolu-
tion of their initial symptoms. One patient with a halo and
no histologic evidence for vasculitis was lost to follow-up.
In this study, 25 patients had negative histology for vascu-
litis, with 16 (64.0%) never receiving steroids, four (16.0%)
treated with steroids, and five (20.0%) lost to follow-up.
Twenty-one of 32 patients were negative for halo, stenosis,
or histology. Fourteen (66.7%) were never treated with
steroids, four (19.0%) were treated with steroids, and three
(14.3%) were lost to follow-up. In this study, the biopsy
rate for patients without the disease was 75.9%. When
examining for halo alone, the sensitivity of CDU for diag-
nosis of TA was 85.7%, the specificity was 92.0%, the PPV
was 75.0%, the NPV was 95.8%, and the diagnostic accu-
racy was 90.6% (Table II). When the presence of a halo or
a hemodynamically significant stenosis was used as a marker
for disease, CDU detection of TA improved with a sensi-
tivity of 100%, a specificity of 80.0%, a PPV of 58.3%, a
NPV of 100%, and a diagnostic accuracy of 90.6% (Table
III).
Next, a metaanalysis was performed to identify all other
published papers related to the use of ultrasonography in
the diagnosis of TA. Six additional studies that met our
criteria were included in a statistical analysis of CDU in the
diagnosis of TA. Stammler et al6 performed a prospective
study of 22 patients with polymyalgia rheumatica who were
analyzed for TA with CDU and subsequent histology of
biopsy specimens. The paper included information on pa-
tients with the halo sign and on patients with stenosis
evident through CDU and compared those with the biopsy
results. The study by Schmidt et al4 was prospective in
design, involving 82 patients and 30 control subjects. To be
considered in this metaanalysis, the relevant data from this
study were extracted. First, all patients who did not un-
dergo a diagnostic biopsy after the results of the CDU were
excluded, eliminating the 30 control subjects and 35 pa-
tients who received no biopsy after CDU. After this, all
indeterminate biopsy results were labeled as negative for
the purposes of the data evaluation. That left a total of 47
patients to be evaluated, with 22 of those positive for a halo,
21 positive biopsy results, five false-positive results, and six
false-negative results. The second study by Schmidt and
Gromnica-Ihle5 originally contained 127 subjects with 127
patient control subjects. However, only those patients with
biopsies performed after CDU were included. This resulted
in a study population of 41, with 24 patients having a halo,
21 positive biopsy results, three false-positive results, and
one false-negative result. A potential problem arose be-
tween the two studies because they had overlapping time
frames; however, both were prospective with different ini-
tial criteria (one with no prior diagnosis, one with prior
diagnosis of polymyalgia rheumatica); thus, no overlap of
patients between the two groups was apparent. The studies
by Schmid et al7 and Vence et al8 were also prospective,
with 20 patients in each included for analysis.
The first analysis of the data from these studies, com-
bined with our own data, addressed the issue of the accu-
racy of ultrasonography in establishing the diagnosis of TA
with just the halo sign compared with histologic results.
Data from all of the studies were included, with a resultant
population of 182 patients to be analyzed. Of these, 75 had
a halo sign present and 72 had a positive biopsy result, and
there were 15 false-positive results and 13 false-negative
results. Two patients were considered to have false-positive
results because of study design, relating to a lack of com-
plete histologic data. The statistical results were calculated,
and the sensitivity of CDU in the diagnosis of TA was
82.2%, the specificity was 86.0%, the PPV was 80.0%, the
NPV was 87.6%, and the diagnostic accuracy was 83.5%
(Table IV).
A second analysis of the data was performed combining
studies with data reporting not only the presence of a halo
Table II. Halo sign only compared with biopsy results
Biopsy  Biopsy  Total
Halo  6 2 8
Halo  1 23 24
Total 7 25 32
Sensitivity was 85.7%, specificity 92.0%, PPV 75.0%, NPV 95.8%, diagnostic
accuracy 90.6%.
P  .0001 with 95% CI.
Table III. Halo sign or hemodynamically significant
stenosis compared with biopsy results
Biopsy  Biopsy  Total
Halo or stenosis  7 5 12
Halo or stenosis  0 20 20
Total 7 25 32
Sensitivity was 100%, specificity 80.0%, PPV 58.3%, NPV 100%, diagnostic
accuracy 90.6%.
P  .001 at 95% CI.
Table IV. Prospective studies evaluating ultrasound scan
halo sign alone as diagnostic marker for TA
No. Halo  Halo  Biopsy  False  False 
Norfolk 32 8 24 7 2 1
Schmidt4 47 22 25 21 6 5
Schmidt5 39 24 15 21 3 1
Stammler6 22 7 15 5 2 0
Schmid7 20 6 14 12 0 6
Venz8 20 8 12 6 2 0
Totals 182 75 105 72 15 13
Sensitivity was 82.2%, specificity 86.0%, PPV 80.0%, NPV 87.6%, and
diagnostic accuracy 83.5%.
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sign but also the presence on CDU of any diagnostic
marker of vessel abnormality, including a halo sign or
stenosis of the vessel. In this case, only our study, the
Schmidt et al4 and Schmidt and Gromnica-Ihle5 studies,
and the Stammler et al6 study were used because they
included all necessary information. In this group, 142
patients, with 83 having a halo or stenoses with CDU, were
analyzed. There were 54 positive biopsy results, 26 false-
positive results, and one false-negative result. Again, two
patients were considered to have false-positive results from
the study design. The statistical analysis revealed that the
sensitivity of CDU for diagnosis of TA looking for halo or
stenosis was 98.2%, the specificity was 69.0%, the PPV was
67.5%, the NPV was 98.3%, and the diagnostic accuracy
was 78.9% (Table V).
DISCUSSION
TA is an inflammatory vasculitis of middle-aged and
elderly patients that is usually associated with branches of
the proximal aorta and the terminal branches of the carotid
arteries, most commonly the temporal arteries. However, it
remains a systemic vasculitis that can affect medium-sized
and large-sized arteries with a wide spectrum of clinical
manifestations. The incidence rate of the disease varies
among different nations, with reported rates between 0.49
and 27.3 per 100,000 persons aged 50 years or older.11 In
the United States, the incidence rate seems to lie some-
where between those figures. In a population-based study
from Olmsted County, Minn, the incidence rate of disease
was reported at an annual rate of 17.8 per 100,000 persons
aged 50 years or older.12 In some populations, TA is the
most frequent form of vasculitis with an increasing inci-
dence as the population ages.1
The successful management of patients with suspected
TA can be a clinical challenge because nonspecific symp-
toms combined with the threat of early disease progression
often forces a physician toward an early temporal artery
biopsy to make a timely diagnosis. TA can lead to debilitat-
ing complications, the most significant of which is perma-
nent blindness in 7% to 14% of untreated patients.13 Also,
other serious vascular complications can occur, including
stroke, myocardial infarction, thoracic aortic dissection,
and occlusion of the major ascending aortic arch branch
vessels. The inflammatory process of TA responds quickly
to high-dose corticosteroid therapy, virtually eliminating
the ultrasound scan–detected inflammatory process in the
vascular tissues in 7 to 54 days.4 Temporal artery biopsy is
still the hallmark of a conclusive diagnosis. Although tem-
poral artery biopsy can be done as a simple outpatient
procedure with minimal risk, complications can arise and
include scalp necrosis, damage to the branches of the facial
nerve, and infection. Also, “skip lesions” are a common
feature in the presentation of TA, with a false-negative rate
of temporal artery biopsy reported in the range of 5% to
9%.14,15 In addition, the sensitivity of temporal artery his-
tology for the diagnosis of TA has been reported in various
studies to be between 56% and 91%.5
Despite the limitations of missing true disease because
of skip lesions at the time of biopsy or during histologic
examination, surgical biopsy with histology is the conclu-
sive gold standard when positive for inflammation. The
timing of the screening surgical biopsy is, therefore, a
difficult clinical decision relying on the extent of physical
findings and clinical symptoms. Treating patients conserva-
tively with the “wait and watch” approach may increase the
likelihood of a positive biopsy; however, in the patients
with true disease, the chances of vascular complications
increase. If a clinician acts too early with screening biopsy,
the pathology may be missed, limiting the future ability of
surgical biopsy to obtain a histologic diagnosis in the face of
recurrent symptoms.
CDU as a screening test has many advantages not
offered by initial screening surgical biopsy. This noninva-
sive method of diagnosis has been shown in multiple series
to have a high sensitivity and NPV for TA.4-9 This exami-
nation is technologist dependant and can be easily per-
formed within 30 minutes by persons comfortable with
general arterial duplex ultrasound scan. CDU has the abil-
ity to evaluate the entire common superficial temporal
artery along with the parietal and frontal branches bilater-
ally, for a total length of about 60 cm of artery. A typical
surgical biopsy samples 5 cm of artery (or less) bilaterally to
limit the morbidity of the operation. The disparity of
evaluating the entire temporal artery vascular bed with the
screening surgical biopsy method, along with the fact that
skip lesions are common, limits surgical biopsy as a screen-
ing test. In response to this, some authors have suggested
that CDU may substitute for surgical biopsy; however, in
this study, approximately 20% of patients were treated with
steroids despite a negative halo, stenosis, and histology for
vasculitis. The physicians were treating patient symptoms
and clinical findings, after the recommendations of the
American College of Rheumatology diagnostic criteria for
TA, in which histology plays a limited role.
The hallmark of TA is an active inflammatory process
with or without the pathognomonic giant cellular infil-
trates; however, ultrasound scan visualizes the edema gen-
erated from this inflammatory process and is an indepen-
dent marker of vascular inflammation. The CDU
examination can scan the entire temporal artery vascular
bed, evaluate for edema or inflammatory stenosis, direct
appropriate biopsies, and locate the region where a biopsy
would have highest yield. This diagnostic method should
Table V. Prospective studies evaluating halo sign and





stenosis Biopsy False False
Norfolk 32 12 20 7 5 0
Schmidt4 47 34 13 21 8 1
Schmidt5 41 30 11 21 9 0
Stammler6 22 7 15 5 2 0
Totals 142 83 59 54 26 1
Sensitivity was 98.2%, specificity 69.0%, PPV 67.5%, NPV 98.3%, and
diagnostic accuracy 78.9%.
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not supplant the established American College of Rheuma-
tology diagnostic criteria for this disorder; rather it should
prevent unnecessary routine surgical biopsy that occurred
in 75% of our study population. Finally, this noninvasive
test can be repeated even in patients with minimal physical
findings or limited symptoms when there appears to be
disease progression.
In conclusion, we suggest that duplex ultrasonography
can visualize the edema of the vascular wall and show
evidence of inflammatory stenoses, which are highly specific
markers of active vasculitis. A positive ultrasound scan
result can prompt a directed surgical biopsy, which would
minimize the chance of a false-negative biopsy result. Con-
versely, a normal temporal artery CDU examination can
eliminate patients who are unlikely to benefit from routine
surgical biopsy of the temporal artery. In the initial evalu-
ation for TA, CDU is a superior screening test for vasculitis
when compared with routine surgical biopsy, with a high
sensitivity for disease, a high NPV for the absence of
disease, and a worldwide experience of consistent and re-
producible results.
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DISCUSSION
Dr Ross T. Lyon (Ithaca, NY). Dr Ricotta, Dr Golden, Dr
Darling, members, and guests. I would like to congratulate the
Norfolk group on a very nice paper and an excellent presentation.
Most of us have found ourselves in the situation of having to
add on an urgent temporal artery biopsy onto a busy operative
schedule even though we knew the likelihood of a positive histo-
logic result was low and then having to face the possibility of
having to repeat the same process over again on the contralateral
side just to make sure that we have not missed the diagnosis. This
paper offers the hope of replacing the knee-jerk suspicion-biopsy
sequence with a noninvasive test that is familiar to all of us, namely,
color duplex ultrasound.
We know that the temporal arteritis produces inflammatory
changes that affect the arteries and often produces stenotic or
occlusive lesions. It makes sense that these changes are also affect-
ing the immediately adjacent tissues. The authors claim to be able
to detect these changes using standard duplex ultrasound. They
have conducted a prospective study looking for the presence of
relative echolucency, which they call a halo sign, representing
periarterial edema or inflammation around the superficial temporal
artery or its branches and/or the presence of stenotic lesions of the
vessel lumen as detected by peak flow velocity measurements.
They correlate these findings with histologic results in the
pathologic diagnosis of temporal arteritis. These results are quite
compelling. The 100% sensitivity and negative predictive values
they have obtained suggests that they did not miss any cases of
temporal arteritis using their CDU technique. The implication is
that if color duplex is negative, there is no need to proceed to an
open biopsy. This information could be quite useful on a Friday
afternoon. Yet, we must be cautious because adopting this ap-
proach could deprive quite a few patients of the thrill of a fresh
surgical incision potentially on both sides of their faces. Somehow
I do not think they will protest too much.
Do we have a new screening test? I suspect so. Do these
findings mean that temporal artery biopsy should not be done in
any case with a negative duplex? I suspect not.
I would be grateful to the authors if they would address the
following issues.
1. You describe the halo sign in the manuscript, but you do not
define it. Could you tell us the precise criteria for a positive halo
sign? Is it or does it have to be circumferential to count? How
thick does it have to be? How long? How echolucent?
2. The grey scale of the B-mode images can be adjusted to give just
about as many shadows or lack of shadows as you like. How did
you standardize the B-mode portion of your CDU exams? And
how did you prevent or minimize the creation of an artifactual
halo sign yet maximize the sensitivity?
3. You used several different transducers and transducer frequen-
cies. Which is the optimal transducer and frequency and which
should be avoided?
4. Does the machine matter?
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5. What are the other conditions that result in a positive halo sign?
6. What is the effect of steroid administration on the halo?
7. And finally, have you begun to abstain from biopsy in patients
with negative duplex findings yet an elevated erythrocyte sedi-
mentation rate?
I would like to thank the Society for the privilege of comment-
ing on this paper and the authors on an excellent manuscript and
study.
Dr Richard J. DeMasi. The finding of a halo sign is subjec-
tive. And in our experience, we were unable to define it in terms of
size around the artery and put a millimeter size on it and so forth.
It was sort of an all-or-none phenomenon. Either patients had the
halo there or they did not. And that was based on the experience of
our technologist who has taken a great interest in this. So, we do
not have the standard objective criteria for presence or absence of
the halo but think we can make the call pretty accurately.
Did we standardize the B-mode of the exam? Well, you need a
high-resolution duplex machine. And like any examination, you
have to optimize the settings. I do not scan, so I am not facile with
the knob-ology. But any good technologist will optimize settings
before any study, and that is particularly true of this study. The
arteries are very superficial. The high-frequency probe, usually the
10 MHz, was the optimal probe. Alternative techniques, such as
stepping the probe off with increased gel, or other techniques were
used to improve the image quality. So, it does take a fair amount of
fiddling around to get the optimal settings.
Does the machine matter? I think it just has to be a good
machine.
Other causes of the halo sign. There have been reports about
other inflammatory conditions that can produce this. And I do not
think that the halo is necessarily specific for temporal or giant cell
arteritis. Any vasculitide that can produce edema in the vessel of the
wall will produce a hypoechoic halo around the vessel. Wegener’s
granulomatosis has been reported to produce this and some other
vasculitides. But in this clinical setting of the patient with head-
ache, fever, elderly, and so forth, it is going to be, in all likelihood,
temporal arteritis.
The effect of steroids on the halo sign, in the New England
Journal paper, they actually studied their patients serially and did
find that as time went on with treatment with corticosteroids the
halo did go away. In the one patient in our study that was halo
negative, but biopsy positive, that was the case. The patient had
been treated for 2 weeks prior with corticosteroids, and we think
that reduced the inflammation and gave us that result. There was
still a residual stenosis there and that allowed us to count it as a
positive when you add stenosis or hemodynamic aberration to the
halo.
Have we gone to the next step yet? Can we safely say that you
do not need to do a temporal artery biopsy yet? I think with
patients with positive findings on duplex, because of the implica-
tions of long-term steroids, I think those patients should still go on
to have a temporal artery biopsy.
In the patient that has a completely negative study, despite
other nonspecific issues such as sed rate elevation, headache, we
would be comfortable in not submitting these patients to temporal
artery biopsy.
And one thing that is different about this approach is when
you think about a temporal artery biopsy, it is an isolated snapshot
that is taken at time X. If you refrain from doing the biopsy at initial
presentation, there is nothing wrong with following that patient
closely clinically and repeating the duplex ultrasound at some point
in the future and that perhaps may increase the diagnosis yield and
not miss patients, which would be potentially disastrous. And I
think that is one of the differences between a screening biopsy and
a screening duplex ultrasound.
Dr Ali F. AbuRahma (Charleston, WV). I enjoyed your
presentation, and I compliment you for going all the way to
complete this study.
I was very much interested in this subject over 10 years ago,
and I spent a few years looking into this. After doing around 50
studies, I gave up, for several reasons: 1, peak systolic velocities
were so inconsistent and there were no standardizations; 2, halo
sign, this was really difficult for us, even when it was pursued by a
technician who had 20 years of experience. I really admire you for
pursuing this.
My question to you is: How did you reach standardization,
not only on the halo sign, but also on peak systolic velocities, since
there is no accepted standard presently in the vascular technology
literature regarding what velocities might constitute stenosis versus
no stenosis?
Regardless, I really enjoyed it and I hope this can work, but it
did not work in my lab.
Dr DeMasi. The question, I believe, was how did we stan-
dardize the criteria for determining stenosis. And we simply de-
fined it as a doubling of the velocity from the artery segment
proximal. And I agree, it is difficult, particularly in these very
tortuous arteries. But we also used additional clues such as post-
stenotic turbulence. And then it is not infrequent that you see
atherosclerotic change in the artery. If all of those things correlate
together, that is how they were standardized.
I have heard others complain, that we have spoken to around
the country, that have tried this and have been somewhat frustrated
with the ability to do this. Like most things in this business, it takes
a dedicated technologist that is really interested in making it
happen, I think.
Dr Robert B. Patterson (Providence, RI). We performed
these studies since the New England Journal of Medicine article
came out as well, and I agree you can subjectively define a halo, but
it remains very subjective.
To follow up on the idea of measuring the stenoses, did you
perform a two-by-two table based just on stenosis? And did that,
independent of the halo sign, have any predictive value? That
would be a more objective, easily obtained piece of information.
Dr DeMasi. That is an interesting question. We did not do
that. And the halo does not necessarily produce hemodynamic
impact, particularly in the acute inflammatory stage. I think what
they get is periarterial edema in the wall and, then, as that resolves,
that is when the stenoses occur. So, that is an interesting question.
We can certainly apply that to our data and let you know.
Dr Bruce A. Perler (Baltimore, Md). Very interesting pre-
sentation. Just a practical question, is this a test for which the lab is
reimbursed?
Dr DeMasi. That is a great question, Bruce. We did these
studies all gratis, and we did it in our office-based lab, so we did not
have the typical hospital issues to deal with. But I think we are
going to go armed with this data to our local people and see if we
can do that. But at the current time—unless, Bob, if you know
something different, speak up—this is not a reimbursable test at
this time. I think it will be.
Dr Michal Golden (Philadelphia, Pa). Your group had re-
cently published a report in the JVS looking at endoleaks with
ultrasound comparing them to CT. Certainly it seems that your lab
is quite accomplished, and you have one technician in your labo-
ratory who does this. Do you think that these study results can be
generalized to the other technicians in your specific laboratory?
How do you feel about a scope further afield from your laboratory
in terms of generalizing it nationally?
Dr DeMasi. That is another good question. These data were
accrued over a 4-year period, so there weren’t a lot of patients, so it
was relatively easy to put one technologist on it, and that is the way we
wanted to do it for purity of the data reasons. But I think the other
technologists in our lab could readily do this. It is not like we have one
superstar that can only do this. I think the others could do it. We just
chose not to do it that way because of the relatively few number of
patients and the fact that she was particularly interested in it. I think
the metaanalysis data that we presented would support the fact that
this is, I think, reproducible and generalizable.
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